Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
Background: Afatinib can be started at a dose lower than the recommended starting dose of 40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), however treatment outcomes in real-world clinical practice remains unclear. Methods: This retro...
Saved in:
Main Authors: | Mau, Ern Poh, Chai, Chee Shee, Chong, Kin Liam, Go, Fuang Ho, Yong, Kek Pang, Harissa, Husainy Hasbullah, Lye, Mun Tho, Ibtisam, Muhamad Nor, Kean, Fatt Ho, Muthukkumaran, Thiagarajan, Azlina, Samsudin, Azza, Omar, Choo, Khoon Ong, Sing, Yang Soon, Sin, Nee Tan, Soon, Hin How |
---|---|
Format: | Article |
Language: | English |
Published: |
AME Publishing Company
2024
|
Subjects: | |
Online Access: | http://ir.unimas.my/id/eprint/44420/3/Does%20dose.pdf http://ir.unimas.my/id/eprint/44420/ https://tlcr.amegroups.org/article/view/83673/html https://dx.doi.org/10.21037/tlcr-23-691 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcomes of patients with EGFR-mutant
advanced NSCLC in a developing country in
Southeast Asia
by: How, Soon Hin, et al.
Published: (2022) -
Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia
by: How, Soon Hin, et al.
Published: (2022) -
Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
by: Poh, Mau Ern, et al.
Published: (2018) -
Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2018) -
Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2019)